The Platelet Derived Growth Factor (PDGF) family of ligands have well established functions in the induction of cell proliferation and migration during development, tissue homeostasis and interactions between tumours and stroma. However, the mechanisms by which these actions are executed are incompletely understood. Here we report a differential phosphoproteomics study, using a SILAC approach, of PDGF-stimulated mouse embryonic fibroblasts (MEFs). 116 phospho-sites were identified as up-regulated and 45 down-regulated in response to PDGF stimulation. These encompass proteins involved in cell adhesion, cytoskeleton regulation and vesicle-mediated transport, significantly expanding the range of proteins implicated in PDGF signalling pathways. Included in the downregulated class was the microtubule bundling protein Collapsin Response Mediator Protein 2 (CRMP2). In response to stimulation with PDGF, CRMP2 was dephosphorylated on Thr514, an event known to increase CRMP2 activity. This was reversed in the presence of micromolar concentrations of the protein phosphatase inhibitor okadaic acid, implicating PDGF-induced activation of protein phosphatase 1 (PP1) in CRMP2 regulation. Depletion of CRMP2 resulted in impairment of PDGF-mediated cell migration in an in vitro wound healing assay. These results show that CRMP2 is required for PDGFdirected cell migration in vitro.
nervous system (CNS) oligodendrocyte precursor (O2A) cells require PDGF signalling both for population expansion and migration through the spinal cord 8 .
PDGF signalling also has significant functions in adult tissue homeostasis and regeneration, acting on cells of mesenchymal origin. PDGF is an established mitogen and chemoattractant for mesenchymal derived cells in vitro 9 and has been studied for its ability to promote wound healing through promoting the migration, proliferation and extracellular matrix deposition by fibroblasts 10 . Ectopic expression of PDGFB in the kidney glomerulus induces expansion of bone marrow derived mesenchymal cells to form a severe mesanagial glomerulopathy and fibrosis 11 . PDGF-BB is a mitogen for vascular smooth muscle cells and activation of PDGF signalling is required for pulmonary arterial hypertension (PAH) and pulmonary arterial remodelling 12 .
The PDGF signalling axis is also implicated in regulation of tumour/stromal cell interactions 13, 14 . PDGF-BB produced by tumours of epithelial origin acts upon adjacent connective tissue cells, pericytes and vascular smooth muscle cells to regulate tumour angiogenesis and tumour-associated fibrosis 15 . PDGF-activated perivascular cells also promote metastasis via tumour-associated macrophages and act on tumour cells that have undergone epithelial-mesenchymal transition (EMT) to promote migration through the extracellular matrix 16, 17 .
Despite the biological significance of these activities, little is known about the downstream intracellular pathways that mediate these responses beyond canonical RTK signalling pathways such as PLC, AKT and MAPK/ERK 2 . To gain further insight into how PDGFs mediate their biological effects we analysed a differential phosphoproteomics dataset of PDGF-stimulated mouse embryo fibroblasts (MEFs) 18 . This shows that, in MEFs, PDGFR activation elicits a broad range of phosphorylation events mediated by downstream Ser/ Thr kinases which impact on mediators of cytoskeletal function and cell motility. In particular, we show that Collapsin response mediator protein-2 (CRMP2) is dephosphorylated in response to PDGF and is required for PDGF-induced cell migration. CRMP2 (also known as dihydropyrimidinase-like 2) is highly expressed in the nervous system and mediates cellular responses downstream of ephrins, neurotrophins and semaphorins, such as neuronal polarity, growth and axonal guidance 19, 20 .
Collectively these results significantly expand the range of proteins and phosphorylation events implicated in PDGF signalling pathways and reveal potential new targets for therapeutic intervention in PDGF signalling. They also reveal a role for CRMP2 in PDGF-induced cell migration which has broad implications for tissue repair and tumour development.
Results

PDGF-induced changes in the phosphoproteome.
We have recently published quantitative SILAC proteomics data identifying changes in the phosphoproteome and proteome of mouse embryonic fibroblasts (MEFs) due to the absence of the intracellular phosphatase domain of Leukocyte Common Antigen-related (LAR) protein tyrosine phosphatase (PRIDE Accession PXD002545 18, 21 ). As part of our analysis of LAR function WT MEFs were stimulated with PDGF, and here we have reanalysed this part of the dataset to identify novel PDGF-dependent phosphorylation events. Full details of the experimental setup and procedures used to obtain the phosphoproteomics and proteomics datasets have been previously described 18 . Methodology relevant to the PDGF-dependent dataset are summarised in Fig. 1A . The Pearson's correlation coefficient for the phosphopeptide ratios measured across the three biological replicates ranged from 0.77 to 0.93 indicating good biological reproducibility ( Fig. 1B) . Within the proteomic dataset, a total of 703 proteins were identified in two or more biological replicates. No significant differences in protein abundance were observed between unstimulated and PDGF stimulated (7 min) cells (Fig. 1C ). In the phosphoproteome dataset, 989 phosphosites from 611 proteins were detected with high localization scores (localization probability >0.75; score difference >5) in three or more experimental replicates ( Supplementary Table S1 ). Within the phosphoproteome dataset, we identified 896 (90.6%) serine, 76 (7.7%) threonine and 17 (1.7%) tyrosine phosphorylation sites ( Fig. 1D ). These results are an accurate reflection of the relative abundance of serine:threonine:tyrosine phosphorylation events in the cell, previously reported to be 88:11:1, and are comparable to those detected downstream of other receptor tyrosine kinases 22, 23 . Being a tyrosine kinase, activation of PDGFR will initiate cell signalling via tyrosine phosphorylation. PDGF-induced tyrosine phosphorylation events have been previously studied using enrichment strategies to increase the relative abundance of tyrosine phosphorylated peptides 24, 25 . As our aim was to gain an understanding of the global signalling landscape regulated by PDGF our enrichment strategy was not selective for either serine, threonine or tyrosine, enabling novel insight into the breadth of biological processes regulated by PDGF. From the 989 phosphopeptides identified, 161 showed a significant change in phosphorylation status upon PDGF stimulation (p < 0.05; >1.5-fold change) ( Fig. 2 ; Supplementary Table S2 ). A total of 116 phosphosites were upregulated and 45 downregulated upon PDGF treatment. Cellular compartment analysis revealed that these PDGF-regulated phosphosites are present on proteins localised throughout the cell, indicating the diversity of PDGF signalling ( Fig. 3 ).
Within this dataset we identified proteins that have previously been shown to be involved in PDGF signalling. For example, the ERK1/2 MAP kinases have been extensively studied and shown to be hyperphosphorylated in response to growth factors such as PDGF [26] [27] [28] . In agreement with these studies, we found increased phosphorylation of ERK1 on Tyr205 (L +PDGF 7min/ M −PDGF ; 15.10) and Thr203 (L +PDGF /M −PDGF ; 14.13), and ERK2 on Tyr185 (L +PDGF /M −PDGF ; 16.77). The phosphorylation of these sites on ERK1/2 is essential for kinase activity. Phosphorylated ERK1/2 mediates diverse physiological functions such as cell growth, survival, cell adhesion, migration and differentiation [26] [27] [28] . We have also identified an increase in the phosphorylation of Bcl2-associated agonist of cell death (BAD) at Ser136 upon PDGF stimulation ( Supplementary Table S2 ). This site is a target for Akt downstream of PDGF and phosphorylation of Ser136 on BAD leads to enhanced cell survival 29 .
Novel PDGF-regulated phosphosites. From 161 phosphosites, we identified 110 (67%) that have not previously been reported as PDGF-regulated sites (PhosphoSitePlus) 30 and are therefore considered novel. Within the phosphoproteomics data set we observed that phosphorylation of Ser303 on insulin receptor substrate 2 (IRS2) increased upon PDGF stimulation (Fig. 2 ). IRS2 is an adaptor protein that binds to the insulin receptor and regulates insulin signalling pathways. PKC isoforms, β and δ, or angiotensin II can induce phosphorylation of Ser303 on IRS2 in endothelial cells leading to inhibition of insulin signalling 31 . This suggests a novel role for PDGF as a negative regulator of insulin signalling, possibly via PKC, known to be activated downstream of PDGF through PLCγ 32, 33 .
After ERK1/2, the next most significant increase in phosphorylation was observed for Ser72 of Ras-related protein Rab7a (Fig. 2 ). Rab7a is a small GTPase involved in the regulation of endo-lysosomal trafficking 34 . Phosphorylation of Rab7a on Ser72 inactivates the protein, thereby impairing the recruitment to endosomal membranes and delaying the transport of EGFR from early to late endosomes 35 . This suggests that PDGFR activates an as yet unidentified kinase which phosphorylates Ser72 on Rab7a indicating an intersection between two major RTKs, PDGFR and EGFR in the regulation of endocytosis. In addition, we observed increased phosphorylation of Slit-Robo GTPase-activating protein 3 (srGAP3) on Ser858 ( Supplementary Table S2 ), a RhoGAP that functions downstream of the Robo receptor and is involved in the development of the nervous system 36, 37 . This site is phosphorylated by protein kinase A (PKA), promoting GAP activity towards Rac1 and inhibition of actin reorganisation in neurons 38 . Following stimulation, 45 novel PDGF-regulated phosphosites were observed to be significantly downregulated including Rho-associated protein kinase 2 (ROCK2; Ser1362), Neurofibromin (NF1; Ser2517), CLIP-associated protein 1 (CLASP1; Ser1193), Parva (Ser14), collapsin response mediator protein 2 (CRMP2; Thr514) and collapsin response mediator protein 4 (CRMP4; Thr514) (Figs 2 and 3; Supplementary Table S2 ). These proteins are mainly involved in regulation of nervous system homeostasis including development, axon formation and growth cone guidance [39] [40] [41] [42] [43] [44] , suggesting a common set of PDGF effectors exist in both fibroblasts and the nervous system and demonstrating that, in addition to the autophosphorylation and phosphorylation of proteins downstream of PDGFR, PDGF can also induce the dephosphorylation of key effectors, some of which regulate cell motility.
Functional analysis of the PDGF-regulated phosphoproteome. Gene Ontology (GO) analysis
of the phosphoproteins regulated by PDGF revealed a number of enriched GO biological processes ( Fig. 4A ; Supplementary Table S3 ). The dominant enriched GO terms were associated with cytoskeletal organisation, MAP kinase signalling, regulation of microtubules and cell adhesion, all processes involved in cell migration. Actin cytoskeleton and microtubule proteins enriched in our phosphoproteome dataset include LIM domain and actin-binding protein 1 (Lima1), Rho guanine nucleotide exchange factor 17 (Arhgef17), Band 4.1-like protein 1 (Epb41l1) and Stathmin (Stmn1) ( Supplementary Table S3 ). We observed an increase in abundance of phosphopeptides belonging to these proteins in response to PDGF stimulation ( Supplementary Table S2 ). We also note the enrichment of biological processes associated with cell adhesion. Reticulon-4 (Rtn4; also known as Nogo), a protein involved in the regulation of neuron development such as neurite growth and axon-axon adhesion 45, 46 was phosphorylated on Ser105 in response to PDGF stimulation ( Supplementary Table S2 ). Paxillin (PXN), an adaptor protein involved in modulation of focal adhesions and cell adhesion pathways, is one of the PDGF-regulated proteins 47, 48 . PDGF is known to regulate PXN activity by promoting the phosphorylation of Tyr118 49-51 . We have not identified this site in our phosphoproteomics dataset, but did identify an increase in phosphorylation of Ser83 ( Supplementary Table S2 ). It has been reported that p38MAPK and ERK1/2 can phosphorylate PXN at Ser83 to regulate neurite extension and chemotaxis in neurons 52, 53 .
KEGG pathway analysis of PDGF-regulated proteins revealed enrichment of signalling pathways implicated in cell migration including focal adhesion, regulation of actin cytoskeleton, adherens junctions and transendothelial cell migration ( Fig. 4B ; Supplementary Table S4 ) [54] [55] [56] . In addition, KEGG analysis of the dataset also identified neurotrophin signalling and axon guidance as PDGF-regulated processes (Fig. 4B) . To identify which kinases are activated upon PDGF stimulation, we used the Kinase Enrichment Analysis (KEA) tool 57 . KEA is a web-based software tool for the prediction of kinase-substrate interactions and links mammalian proteins with the upstream kinases that potentially phosphorylate them. KEA analysis revealed a significant enrichment of substrates for ribosomal protein S6 kinase (RSK2) ( Fig. 4C ; Supplementary Table S5 ). RSK2 promotes cell motility and invasion by mediating the activity of integrins and actin cytoskeleton rearrangement [58] [59] [60] [61] . RSK2 can also promote migration in epithelial cells through the FGFR2-p38 kinase axis pathway 62 . KEA analysis also identified other over-represented kinases including dual specificity mitogen-activated protein kinase kinase (MEK1) and c-Jun N-terminal kinase (JNK1) (Fig. 4C ). The activities of both kinases are known to be regulated by growth factors such as PDGF and they are involved in regulation of many cellular functions including cell migration 63, 64 . CRMP2 is a novel PDGF-regulated protein. We elected to further analyse the role of collapsin response mediator protein 2 (CRMP2) as an example of a novel PDGF-induced dephosphorylation target found within our dataset. CRMP2 regulates cytoskeletal remodelling, neurotransmission and axon guidance via its ability to promote microtubule assembly [65] [66] [67] . Consistent with this, GSK3β has been shown to phosphorylate CRMP2 at Thr509, Thr514 and Ser518 thereby inhibiting CRMP2 activity leading to microtubule depolymerization and destabilization 68, 69 . Within our dataset a doubly phosphorylated peptide from CRMP2 (pThr514; pSer518) was significantly downregulated following PDGF stimulation ( Fig. 5A ; Supplementary Table S2 ). Western blotting with a phosphospecific antibody recognising the highly conserved Thr514 residue confirmed that phosphorylation of CRMP2 at Thr514 was significantly decreased following PDGF stimulation compared to non-stimulated cells (Fig. 5B-D) . These data clearly show that PDGF regulates the dephosphorylation of CRMP2 at Thr514, an event known to activate the protein.
It has been previously shown that PP1 or PP2A can dephosphorylate CRMP2 at Ser518, Thr514 or Thr509 70, 71 . We therefore tested the effect of okadaic acid on CRMP2 phosphorylation at Thr514 following PDGF stimulation in MEFs. PP2A is inhibited at low concentrations (<1 μM) of okadaic acid, whereas higher concentrations (>1 μM) inhibit PP1 72, 73 . Western blot analysis showed no significant changes in PDGF-regulated CRMP2 dephosphorylation when okadaic acid was added at low (0.01 μM or 1 μM) concentrations (Fig. 6A ). However, higher concentrations of okadaic acid (1.5 μM) inhibited the dephosphorylation of CRMP2 at Thr514 in response to PDGF stimulation (Fig. 6A,B) . Together, these observations suggest that PDGF signalling acts via PP1 to dephosphorylate CRMP2 at Thr514. 
CRMP2 depletion inhibits cell migration in MEFs.
CRMP2 has been widely studied in the nervous system where it regulates neuronal migration and axon guidance 74, 75 . CRMP2 also regulates polarisation and migration of T lymphocytes within the immune system 76, 77 . However, the regulation of cell migration by CRMP2 outside the nervous and immune systems has not been studied. PDGF induced cell migration has been widely studied in fibroblasts, revealing roles for Rac1, MAPK/ERK and JNK kinases 64, 78 . To establish if CRMP2 has a role in PDGF induced cell migration in MEFs we examined the consequences of RNAi-mediated depletion of CRMP2 in a standard in vitro scratch wound healing assay. Confluent MEFs were transfected with a CRMP2 directed SMARTpool of siRNAs and non-silencing control siRNA, serum starved and wounded in the presence of PDGF (Fig. 7) . The results of this experiment clearly show that siRNA mediated depletion of CRMP2 (Fig. 7A ) significantly inhibits the rate of wound closure in the presence of PDGF (Fig. 7B,C) . This was confirmed using three individual siRNAs against CRMP2 ( Supplementary Fig. S1 ). These observations confirm that CRMP2, identified in our dataset as a novel PDGF downstream effector, is required for PDGF-stimulated cell migration in MEFs. Supplementary Fig. S3. (B) Western blots were quantified and ratios of pCRMP2 to CRMP2 were plotted (*P < 0.05).
Scientific RepoRts | 7: 3970 | DOI:10.1038/s41598-017-04015-x Discussion PDGF ligands and their cognate receptors are firmly established as key mediators of mesenchymal cell migration in developmental, homeostatic and pathological processes [2] [3] [4] [5] . However, the downstream effectors of the PDGF pathway are incompletely characterised. In order to identify PDGF-regulated protein phosphorylation events and expand the range of PDGF mediators, we undertook a study of PDGF-stimulated MEFs using a differential phosphoproteomics approach 18 . The aim of this study was to significantly expand the repertoire of PDGF pathway effectors and to identify novel candidates that might mediate PDGF induced cell migration. Here we report the identification of 989 phosphosites from 611 proteins in our screen. Out of these, 116 phosphopeptides were significantly upregulated in PDGF-stimulated cells, many of which are novel PDGF-regulated phosphosites. Phosphoproteins regulated by PDGF play a role in cellular signalling pathways that mediate cell adhesion, endocytosis and vesicular trafficking, cytoskeletal organization and nuclear function.
We also report the identification of 45 phosphopeptides that are significantly down-regulated in response to PDGF stimulation. These include proteins such as CLASP1 and CRMP2. CRMP2 is of interest as an effector of PDGF-mediated cell migration as it has a well-established role as mediator of axon guidance, growth cone collapse and cell migration in neurons 67, 75, 79 . Phosphoproteomic and western blotting analysis indicated that, in MEFs, PDGF mediates dephosphorylation of CRMP2 at Thr514. In neuronal cells this site is phosphorylated by GSK3β leading to destabilization of microtubules and neurite degeneration, whereas the dephosphorylated form of CRMP2 Thr514 promotes microtubule stabilisation and sustains neurite outgrowth 68, 69, 80 . This indicates that dephosphorylation of CRMP2 involves the activation of a protein phosphatase(s). We showed that micromolar concentrations of okadaic acid, a serine/threonine phosphatase inhibitor, restored the phosphorylation of CRMP2 at Thr514. This is most likely due to preferential inhibition of protein phosphatase 1 (PP1) 72, 73 . CRMP2 is not however dephosphorylated in non-stimulated cells showing that PDGF pathway activation is essential for the CRMP2 directed activity of this phosphatase. Given the intersection of CRMP2 in neuronal cells and MEFs we were interested to learn if CRMP2 was required for PDGF induced cell migration. Depletion of CRMP2 resulted in impairment of cell migration in a scratch wound assay in the presence of PDGF showing that it is required for PDGF induced cell migration in MEFs.
Our quantitative phosphoproteomics study has significantly expanded the known repertoire of PDGF effectors and provided a resource for further experimental studies. The novelty of our findings is highlighted by the fact that we have identified a role for CRMP2 in PDGF-regulated cell migration, a fundamental biological process closely linked to developmental processes and progression of disease.
Methods
Phosphoproteomics and bioinformatics. Details of the experimental setup for the quantitative phosphoproteomics experiments have been previously described 18 . Within the MaxQuant output, phosphorylation sites were considered to be localised correctly if the localisation probability was at least 0.75 (75%) and the score difference at least 5. Significance testing was performed in the Perseus software environment, which is part of MaxQuant (Perseus version 1.5.0.15; www.perseus.framework.org), using a Student's t-test on log 2 transformed ratios and controlled with a Benjamini-Hochberg FDR threshold of 0.05. Peptides quantified in three or more experimental repeats were deemed significantly changed and regulated by PDGF if they had a p-value of <0.05 and a ratio of <0.667 or >1.5 (at least a 1.5-fold change in abundance). The COMPARTMENTS database 81 was used to assign proteins to subcellular localisations. Protein network visualization was performed using Cytoscape (version 3.3.0) 82 . DAVID (Database for Annotation, Visualization and Integrated Discovery) 83 was used to identify over-represented KEGG pathways [54] [55] [56] (threshold count, 2; EASE score, 0.05) and REVIGO 84 was used for identification and visualisation of over-represented GO terms. Kinases upstream of the identified PDGFregulated phosphopeptides were predicted using Kinase Enrichment Analysis (KEA) 57 .
Reagents and antibodies. Antibodies against CRMP2 (#9393), CRMP2 Thr514 (#9397), and phospho-threonine (#9381) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies against ERK1/2 (sc-514302) and ERK Thr202/Tyr204 (sc-136521) were purchased from Santa Cruz Biotechnology (Dallas, TX), and against tubulin (T6199) from Sigma-Aldrich Company Ltd (U.K.). The anti-Alix antibody was a gift from Carl Hendrik Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden) 85 . Goat anti-mouse-IgG IRDye-conjugated antibody (925-68070) and goat anti-rabbit-IgG (925-68071) HRP-conjugated antibodies were from LI-COR Biosciences (Lincoln, NE). Recombinant human PDGF-BB (#8912) was purchased from Cell Signaling Technology and okadaic acid was purchased from Calbiochem (Hertfordshire, UK).
Cell culture. Mouse embryonic fibroblasts (MEFs) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 10 mg/mL streptomycin, and 250 μg/mL amphotericin B. For growth factor stimulation experiments, cells were grown to 80% confluence and starved for 16 h in serum-free DMEM before being treated with 20 ng/mL recombinant PDGF-BB at 37 °C. In some experiments, cells were incubated with either 0.01 μM, 1 μM or 1.5 μM okadaic acid.
Cell lysis and immunoblotting. Cell lysates were prepared, separated by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted using previously described protocols 18 . Immunoblots were visualised using fluorescence detection on the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln NE). Densitometric analysis was carried out using ImageJ 86 .
RNA interference. Cells were transiently transfected with 80 pmol of SMARTpool or individual
ONTARGETplus siRNA for murine CRMP2 (L-041965-01-0005, J-041965-09-002, J-041965-10-002, J-041965-11-002; Dharmacon, Lafayette, CO) using Lipofectamine RNAiMAX (Life Technologies, Paisley, UK) as described elsewhere 87 . Nonsilencing control (NSC) siRNA was used as a control for each experiment.
Scratch wound assay. Cells were plated in 96-well cell culture plates and cultured to confluency. Cells were serum starved overnight. Scratch wounds were made using an automated wound maker (Essen BioScience, Hertfordshire, UK), cells were stimulated with 20 ng/ml PDGF, and images collected at hourly intervals post-wounding using an IncuCyte ZOOM imaging system (Essen BioScience, Hertfordshire, UK). Data Availability. The mass spectrometry proteomics data, including the output from MaxQuant 88 , used in this analysis have been previously deposited on the Proteome Xchange Consortium via the PRIDE partner repository with the dataset identifier PXD002545 18, 21 .
